The Maternal Embryonic Leucine Zipper Kinase (MELK) has been implicated as a cancer dependency and putative drug target in multiple cancer types, including melanoma, colorectal cancer, and triple-negative breast cancer (Chung et al., 2012; Speers et al., 2016; Wang et al., 2014; Ganguly et al., 2014a; Ganguly et al., 2014b; Janostiak et al., 2017). This evidence concerns the gene MELK and melanoma.